Dihydrofolate reductase inhibitors as antimicrobial agents and their potentiation by sulfonamides.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000962:Antimalarials / Q000494:pharmacology; D000981:Antiprotozoal Agents / Q000494:pharmacology; D002463:Cell Membrane Permeability; D055598:Chemical Phenomena; D002621:Chemistry; D004338:Drug Combinations; D004357:Drug Synergism; D005492:Folic Acid / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000494:pharmacology / Q000633:toxicity; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007668:Kidney / Q000502:physiology; D007778:Lactobacillus / Q000187:drug effects; D002727:Proguanil / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology*; D013420:Sulfamethoxazole / Q000008:administration & dosage; D013449:Sulfonamides / Q000494:pharmacology*; D014295:Trimethoprim / Q000008:administration & dosage / Q000652:urine
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D000981:Antiprotozoal Agents; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013449:Sulfonamides; D005492:Folic Acid; D014295:Trimethoprim; D013420:Sulfamethoxazole; D002727:Proguanil